{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:35:16Z","timestamp":1790789716845,"version":"4.1.0"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA217798"],"award-info":[{"award-number":["P01CA217798"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA273319"],"award-info":[{"award-number":["R01CA273319"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA273349"],"award-info":[{"award-number":["R01CA273349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA200466"],"award-info":[{"award-number":["U01CA200466"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.canlet.2024.216876","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T11:25:09Z","timestamp":1712748309000},"page":"216876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies"],"prefix":"10.1016","volume":"590","author":[{"given":"Luke J.","family":"Weisbrod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Thiraviyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghupathy","family":"Vengoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Shonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder K.","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-1167","authenticated-orcid":false,"given":"Afshin","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216876_bib1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/neuonc\/nox021","article-title":"Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?","volume":"19","author":"Cohen","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib2","series-title":"Declines in Cancer Death Rates Among Youth: United States, 2001-2021","first-page":"1","author":"Curtin","year":"2023"},{"key":"10.1016\/j.canlet.2024.216876_bib3","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3811","article-title":"Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma","volume":"14","author":"Jones","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216876_bib5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ccell.2018.11.015","article-title":"Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression","volume":"35","author":"Larson","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","article-title":"Contemporary survival endpoints: an international diffuse intrinsic pontine glioma registry study","volume":"19","author":"Cooney","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11912-020-0877-0","article-title":"Targeting and therapeutic monitoring of H3K27M-mutant glioma","volume":"22","author":"Wierzbicki","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.canlet.2024.216876_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2024.216876_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1501354","article-title":"Mutations in chromatin machinery and pediatric high-grade glioma","volume":"2","author":"Lulla","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2024.216876_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/aps.2013.161","article-title":"EZH2: biology, disease, and structure-based drug discovery","volume":"35","author":"Tan","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2024.216876_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nsmb.2669","article-title":"Transcriptional regulation by Polycomb group proteins","volume":"20","author":"Di Croce","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2024.216876_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nm.4296","article-title":"Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas","volume":"23","author":"Piunti","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41698-017-0033-y","article-title":"Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event","volume":"1","author":"Koschmann","year":"2017","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1126\/science.aao4750","article-title":"Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq","volume":"360","author":"Filbin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216876_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/neuonc\/noaa251","article-title":"A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR","volume":"23","author":"Sievers","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3171\/2017.2.PEDS1665","article-title":"Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases","volume":"20","author":"Hamisch","year":"2017","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.canlet.2024.216876_bib18","first-page":"108","article-title":"Brainstem stereotactic biopsy sampling in children","volume":"104","author":"Pincus","year":"2006","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.canlet.2024.216876_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3171\/2020.4.PEDS2092","article-title":"Safety and efficacy of brainstem biopsy in children and young adults","volume":"26","author":"Hersh","year":"2020","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.canlet.2024.216876_bib20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2008.13.5293","article-title":"Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial","volume":"26","author":"Laughton","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib21","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(82)91524-0","article-title":"Incidence of second malignant neoplasms in children: results of an international study","volume":"2","author":"Mike","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2024.216876_bib22","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2008.01.050","article-title":"Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose","volume":"72","author":"Hua","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2024.216876_bib23","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2005.00.703","article-title":"Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma","volume":"23","author":"Mulhern","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2214\/ajr.105.1.43","article-title":"The treatment and prognosis of medulloblastoma in children. A study of 82 verified cases","volume":"105","author":"Bloom","year":"1969","journal-title":"Am. J. Roentgenol. Radium Ther. Nucl. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib25","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S1470-2045(17)30030-X","article-title":"Prevention of radiotherapy-induced neurocognitive dysfunction in survivors of paediatric brain tumours: the potential role of modern imaging and radiotherapy techniques","volume":"18","author":"Ajithkumar","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2176\/nmc.ra.2018-0044","article-title":"MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas and MGMT silencing to temozolomide sensitivity in IDH-mutant gliomas","volume":"58","author":"Abe","year":"2018","journal-title":"Neurol. Med.-Chir."},{"key":"10.1016\/j.canlet.2024.216876_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28011","article-title":"Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: a review of past, current, and emerging therapies","volume":"67","author":"Guerra-Garcia","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2024.216876_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2012.87","article-title":"Paediatric and adult malignant glioma: close relatives or distant cousins?","volume":"9","author":"Jones","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib29","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","article-title":"The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location","volume":"54","author":"Liu","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216876_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.trecan.2023.02.003","article-title":"Oncohistones in brain tumors: the soil and seed","volume":"9","author":"Andrade","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2024.216876_bib32","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","article-title":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","volume":"130","author":"Castel","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2024.216876_bib33","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-015-1405-4","article-title":"Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers","volume":"129","author":"Korshunov","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2024.216876_bib34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.20892\/j.issn.2095-3941.2019.0143","article-title":"Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis","volume":"16","author":"Xie","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.canlet.2024.216876_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrg.2016.13","article-title":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","volume":"17","author":"Feinberg","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2024.216876_bib36","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.molcel.2018.05.023","article-title":"Capturing the onset of PRC2-mediated repressive domain formation","volume":"70","author":"Oksuz","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41594-018-0036-6","article-title":"Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2","volume":"25","author":"Hojfeldt","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2024.216876_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40478-022-01336-5","article-title":"A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis","volume":"10","author":"Dhar","year":"2022","journal-title":"Acta Neuropathol Commun."},{"key":"10.1016\/j.canlet.2024.216876_bib39","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1158\/1078-0432.CCR-10-0438","article-title":"A distinct spectrum of copy number aberrations in pediatric high-grade gliomas","volume":"16","author":"Bax","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030313","article-title":"Mesenchymal transition and PDGFRA amplification\/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas","volume":"7","author":"Puget","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216876_bib41","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/0008-5472.CAN-13-1491","article-title":"Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas","volume":"73","author":"Paugh","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pbc.24060","article-title":"Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma","volume":"58","author":"Grill","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2024.216876_bib43","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1073\/pnas.1101657108","article-title":"Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma","volume":"108","author":"Monje","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216876_bib44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib45","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","article-title":"Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas","volume":"24","author":"Bender","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ng.2925","article-title":"Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma","volume":"46","author":"Taylor","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216876_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.2936","article-title":"Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations","volume":"46","author":"Buczkowicz","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216876_bib48","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216876_bib49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/ng.2950","article-title":"Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma","volume":"46","author":"Fontebasso","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216876_bib50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","article-title":"Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma","volume":"22","author":"Sturm","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib51","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.2011.35.5677","article-title":"Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma","volume":"29","author":"Paugh","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib52","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2159-8290.CD-12-0426","article-title":"Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN","volume":"3","author":"Bjerke","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216876_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","article-title":"Diffuse brainstem glioma in children: critical review of clinical trials","volume":"7","author":"Hargrave","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.radonc.2014.01.013","article-title":"Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial","volume":"111","author":"Zaghloul","year":"2014","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib55","unstructured":"Hypofractionated Radiotherapy for Recurrent DIPG."},{"key":"10.1016\/j.canlet.2024.216876_bib56","unstructured":"Stereotactic biopsy split-course radiation therapy in diffuse midline glioma, sport-dmg study."},{"key":"10.1016\/j.canlet.2024.216876_bib57","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00381-019-04420-9","article-title":"Proton therapy for newly diagnosed pediatric diffuse intrinsic pontine glioma","volume":"36","author":"Muroi","year":"2020","journal-title":"Childs Nerv Syst."},{"key":"10.1016\/j.canlet.2024.216876_bib58","unstructured":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound with Doxorubicin for Treatment of Pediatric DIPG."},{"key":"10.1016\/j.canlet.2024.216876_bib59","unstructured":"A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG."},{"key":"10.1016\/j.canlet.2024.216876_bib60","unstructured":"FUS Etoposide for DMG - A Feasibility Study."},{"key":"10.1016\/j.canlet.2024.216876_bib61","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3171\/2021.3.PEDS20738","article-title":"Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial","volume":"28","author":"McCrea","year":"2021","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.canlet.2024.216876_bib62","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2967\/jnumed.118.218792","article-title":"A distinct advantage to intraarterial delivery of (89)Zr-bevacizumab in PET imaging of mice with and without osmotic opening of the blood-brain barrier","volume":"60","author":"Lesniak","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11060-016-2099-8","article-title":"Superselective intraarterial cerebral infusion of cetuximab after osmotic blood\/brain barrier disruption for recurrent malignant glioma: phase I study","volume":"128","author":"Chakraborty","year":"2016","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib64","first-page":"4048","article-title":"Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors","volume":"61","author":"Modak","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib65","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/mpo.10151","article-title":"Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor","volume":"39","author":"Modak","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib66","first-page":"534","article-title":"Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9","volume":"20","author":"Modak","year":"2005","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.canlet.2024.216876_bib67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11060-015-1788-z","article-title":"Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy","volume":"123","author":"Kramer","year":"2015","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib68","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(18)30322-X","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial","volume":"19","author":"Souweidane","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib69","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/neuonc\/noad105","article-title":"PNOC015: repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"25","author":"Mueller","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib70","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216876_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","article-title":"Immunotherapy: tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","article-title":"Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment","volume":"5","author":"Scarfo","year":"2017","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.canlet.2024.216876_bib73","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216876_bib74","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib75","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5650\/jos.60.537","article-title":"Structures, biosynthesis, and functions of gangliosides--an overview","volume":"60","author":"Yu","year":"2011","journal-title":"J. Oleo Sci."},{"key":"10.1016\/j.canlet.2024.216876_bib76","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib77","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-015-0399-5","article-title":"Dinutuximab: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216876_bib78","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/15592294.2016.1278095","article-title":"Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: insight into epigenetic therapies","volume":"12","author":"Maury","year":"2017","journal-title":"Epigenetics"},{"key":"10.1016\/j.canlet.2024.216876_bib79","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib80","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a novel CAR-T therapeutic target for glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.canlet.2024.216876_bib81","unstructured":"C7R-GD2.CAR T Cells for Patients with GD2-Expressing Brain Tumors (GAIL-B)."},{"key":"10.1016\/j.canlet.2024.216876_bib82","unstructured":"GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG).."},{"key":"10.1016\/j.canlet.2024.216876_bib83","unstructured":"Study of B7-H3-specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors.."},{"key":"10.1016\/j.canlet.2024.216876_bib84","unstructured":"Study of B7-H3, EGFR806, HER2, and IL13-Zetakine (Quad) CAR T cell locoregional immunotherapy for pediatric diffuse intrinsic pontine glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors."},{"key":"10.1016\/j.canlet.2024.216876_bib85","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216876_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.216876_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/764213","article-title":"Cellular-based immunotherapies for patients with glioblastoma multiforme","volume":"2012","author":"Xu","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.canlet.2024.216876_bib88","unstructured":"Brain Stem Gliomas Treated with Adoptive Cellular Therapy during Focal Radiotherapy Recovery Alone or with Dose-Intensified Temozolomide (Phase I)."},{"key":"10.1016\/j.canlet.2024.216876_bib89","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216876_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216182","article-title":"Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions","volume":"562","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216876_bib92","unstructured":"Pembrolizumab in Treating Younger Patients with Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma."},{"key":"10.1016\/j.canlet.2024.216876_bib93","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-022-01646-7","article-title":"Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer","volume":"39","author":"Bose","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib94","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2021.08.018","article-title":"Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and\/or metastatic cervical cancer","volume":"163","author":"O'Malley","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191926","article-title":"Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody","volume":"13","author":"Gombos","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216876_bib96","unstructured":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG."},{"key":"10.1016\/j.canlet.2024.216876_bib97","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2002.20.4.1063","article-title":"Quantitatively determined survivin expression levels are of prognostic value in human gliomas","volume":"20","author":"Chakravarti","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib98","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/cncr.11122","article-title":"Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis","volume":"97","author":"Kajiwara","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216876_bib99","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1158\/1078-0432.CCR-17-2778","article-title":"Survivin monoclonal antibodies detect survivin cell surface expression and inhibit tumor growth in vivo","volume":"24","author":"Fenstermaker","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib100","article-title":"Wild type, dEX3 and 2B survivin isoforms localize to the tumor cell plasma membrane, are secreted in exosomes, and interact with extracellular tubulin","volume":"28","author":"Figel","year":"2021","journal-title":"Biochem Biophys Rep."},{"key":"10.1016\/j.canlet.2024.216876_bib101","unstructured":"A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma."},{"key":"10.1016\/j.canlet.2024.216876_bib102","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"Gallego Perez-Larraya","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib103","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Martinez-Velez","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216876_bib104","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Martinez-Velez","year":"2019","journal-title":"Acta Neuropathol Commun."},{"key":"10.1016\/j.canlet.2024.216876_bib105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-065X.2012.01149.x","article-title":"Amino acid catabolism: a pivotal regulator of innate and adaptive immunity","volume":"249","author":"McGaha","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2024.216876_bib106","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fonc.2018.00370","article-title":"Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer","volume":"8","author":"Fox","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib107","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20020121","article-title":"Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase","volume":"196","author":"Frumento","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib108","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216876_bib109","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI31911","article-title":"Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase","volume":"117","author":"Sharma","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216876_bib110","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.immuni.2010.11.022","article-title":"Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice","volume":"33","author":"Sharma","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.216876_bib111","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1182\/blood-2008-12-195354","article-title":"Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes","volume":"113","author":"Sharma","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216876_bib112","unstructured":"Pediatric Trial of Indoximod with Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG."},{"key":"10.1016\/j.canlet.2024.216876_bib113","doi-asserted-by":"crossref","first-page":"74380","DOI":"10.18632\/oncotarget.11814","article-title":"Discovery and clinical introduction of first-in-class imipridone ONC201","volume":"7","author":"Allen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216876_bib114","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aac4374","article-title":"ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2alpha kinases","volume":"9","author":"Kline","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2024.216876_bib115","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216876_bib116","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","article-title":"Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201","volume":"145","author":"Chi","year":"2019","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib117","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3171\/2019.2.PEDS18480","article-title":"First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report","volume":"23","author":"Hall","year":"2019","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.canlet.2024.216876_bib118","article-title":"Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy","volume":"4","author":"Gardner","year":"2022","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.canlet.2024.216876_bib119","unstructured":"ONC201 in H3 K27M-Mutant Diffuse Glioma Following Radiotherapy (The ACTION Study)."},{"key":"10.1016\/j.canlet.2024.216876_bib120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/bs.apcsb.2019.11.009","article-title":"Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions","volume":"121","author":"Klein","year":"2020","journal-title":"Adv Protein Chem Struct Biol."},{"key":"10.1016\/j.canlet.2024.216876_bib121","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216876_bib122","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(-) metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib123","unstructured":"Abemaciclib in Children with DIPG or Recurrent\/Refractory Solid Tumors.."},{"key":"10.1016\/j.canlet.2024.216876_bib124","unstructured":"Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis."},{"key":"10.1016\/j.canlet.2024.216876_bib125","article-title":"Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine","volume":"2","author":"Green","year":"2020","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.canlet.2024.216876_bib126","unstructured":"Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma."},{"key":"10.1016\/j.canlet.2024.216876_bib127","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720930629","article-title":"Selinexor in relapsed\/refractory multiple myeloma","volume":"11","author":"Richter","year":"2020","journal-title":"Ther Adv Hematol."},{"key":"10.1016\/j.canlet.2024.216876_bib128","unstructured":"A Study of the Drug Selinexor with Radiation Therapy in Patients with Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)."},{"key":"10.1016\/j.canlet.2024.216876_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12450","article-title":"An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors","volume":"8","author":"Abdelbaki","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.canlet.2024.216876_bib130","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/cdd.2016.7","article-title":"Exposure of phosphatidylserine on the cell surface","volume":"23","author":"Nagata","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2024.216876_bib131","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.bbamem.2006.10.018","article-title":"A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death","volume":"1758","author":"Taha","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2024.216876_bib132","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.18632\/oncotarget.2214","article-title":"Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors","volume":"5","author":"Blanco","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216876_bib133","unstructured":"A Study of BXQ-350 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)."},{"key":"10.1016\/j.canlet.2024.216876_bib134","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1535-7163.MCT-20-0774","article-title":"Preclinical and early clinical development of PTC596, a novel small-molecule tubulin-binding agent","volume":"20","author":"Jernigan","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2024.216876_bib135","unstructured":"A Phase 1b Study of PTC596 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma."},{"key":"10.1016\/j.canlet.2024.216876_bib136","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2019.00092","article-title":"Current murine models and new developments in H3K27M diffuse midline gliomas","volume":"9","author":"Welby","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib137","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2020.12.013","article-title":"A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening","volume":"500","author":"Zhang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216876_bib138","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3389\/fonc.2019.01418","article-title":"Patient-derived orthotopic xenograft models of pediatric brain tumors: in a mature phase or Still in its infancy?","volume":"9","author":"Hermans","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib139","article-title":"Advanced pediatric diffuse pontine glioma murine models pave the way towards precision medicine","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216876_bib140","article-title":"In vivo and ex vivo pediatric brain tumor models: an overview","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib141","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ccell.2017.09.014","article-title":"H3.3(K27M) cooperates with Trp53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas","volume":"32","author":"Pathania","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib142","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/2159-8290.CD-23-0004","article-title":"A compendium of syngeneic, transplantable pediatric high-grade glioma models reveals subtype-specific therapeutic vulnerabilities","volume":"13","author":"McNicholas","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216876_bib143","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/cancers5020430","article-title":"Epigenetic modulating agents as a new therapeutic approach in multiple myeloma","volume":"5","author":"Maes","year":"2013","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216876_bib144","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216876_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216121","article-title":"The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy","volume":"559","author":"Moran","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216876_bib146","article-title":"Efficacy of panobinostat for the treatment of multiple myeloma","volume":"2020","author":"Eleutherakis-Papaiakovou","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib147","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","article-title":"Transcriptional dependencies in diffuse intrinsic pontine glioma","volume":"31","author":"Nagaraja","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib148","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccell.2019.09.005","article-title":"Re-Programing chromatin with a bifunctional LSD1\/HDAC inhibitor induces therapeutic differentiation in DIPG","volume":"36","author":"Anastas","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib149","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","article-title":"Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas","volume":"35","author":"Krug","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108994","article-title":"Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG","volume":"35","author":"Ehteda","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.216876_bib152","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/neuonc\/noaa249","article-title":"Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naive diffuse midline glioma models","volume":"23","author":"Vitanza","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.742561","article-title":"Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas","volume":"12","author":"Leszczynska","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.canlet.2024.216876_bib154","doi-asserted-by":"crossref","first-page":"13498","DOI":"10.1021\/ja5060934","article-title":"Strategy for \"detoxification\" of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2","volume":"136","author":"Brown","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2024.216876_bib155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models","volume":"12","author":"Hennika","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216876_bib156","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216876_bib157","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.3716","article-title":"Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma","volume":"20","author":"Hashizume","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib158","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fonc.2015.00147","article-title":"Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma","volume":"5","author":"Buczkowicz","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020490","article-title":"Combined targeting of mutant p53 and Jumonji family histone demethylase augments therapeutic efficacy of radiation in H3K27M DIPG","volume":"21","author":"Nikolaev","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216876_bib160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216876_bib161","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib162","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.4293","article-title":"EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas","volume":"23","author":"Mohammad","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216876_bib163","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/PAS.0b013e318294e817","article-title":"Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas","volume":"37","author":"Ballester","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2024.216876_bib164","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1158\/1078-0432.CCR-12-2119","article-title":"Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade","volume":"19","author":"Chu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/stem.254","article-title":"NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts","volume":"28","author":"Fan","year":"2010","journal-title":"Stem Cell."},{"key":"10.1016\/j.canlet.2024.216876_bib166","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/NEN.0000000000000216","article-title":"Disrupting NOTCH slows diffuse intrinsic pontine glioma growth, enhances radiation sensitivity, and shows combinatorial efficacy with bromodomain inhibition","volume":"74","author":"Taylor","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.canlet.2024.216876_bib167","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/febs.13112","article-title":"The controversial role of the Polycomb group proteins in transcription and cancer: how much do we not understand Polycomb proteins?","volume":"282","author":"Scelfo","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.canlet.2024.216876_bib168","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","article-title":"Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer","volume":"7","author":"Sauvageau","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib169","doi-asserted-by":"crossref","first-page":"62962","DOI":"10.18632\/oncotarget.18002","article-title":"BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma","volume":"8","author":"Kumar","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216876_bib170","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1158\/1541-7786.MCR-20-0099","article-title":"Diffuse intrinsic pontine glioma cells are vulnerable to mitotic abnormalities associated with BMI-1 modulation","volume":"18","author":"Senthil Kumar","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108286","article-title":"Senescence induced by BMI1 inhibition is a therapeutic vulnerability in H3K27M-mutant DIPG","volume":"33","author":"Balakrishnan","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.216876_bib172","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrm3823","article-title":"Cellular senescence: from physiology to pathology","volume":"15","author":"Munoz-Espin","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216876_bib173","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216876_bib174","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216876_bib175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-018-0713-7","article-title":"Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer","volume":"37","author":"Liu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105329","article-title":"Cancer cell intrinsic TIM-3 induces glioblastoma progression","volume":"25","author":"Guo","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.canlet.2024.216876_bib177","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","article-title":"TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory","volume":"41","author":"Ausejo-Mauleon","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib178","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1158\/0008-5472.CAN-12-1683","article-title":"Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors","volume":"72","author":"Manzoor","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216876_bib179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/sct.1989.5.1","article-title":"Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases","volume":"5","author":"Chiannilkulchai","year":"1989","journal-title":"Sel. Cancer Ther."},{"key":"10.1016\/j.canlet.2024.216876_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216141","article-title":"Milk\/colostrum exosomes: a nanoplatform advancing delivery of cancer therapeutics","volume":"561","author":"Wallen","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216876_bib181","article-title":"Exosomal delivery of cannabinoids against cancer","volume":"181","author":"Kaur","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216876_bib182","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2217\/fon.12.111","article-title":"The future of glioma treatment: stem cells, nanotechnology and personalized medicine","volume":"8","author":"Rahman","year":"2012","journal-title":"Future Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib183","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2012.06.028","article-title":"Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach","volume":"162","author":"Fang","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2024.216876_bib184","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nec.2012.04.006","article-title":"Nanotechnology applications for glioblastoma","volume":"23","author":"Nduom","year":"2012","journal-title":"Neurosurg. Clin."},{"key":"10.1016\/j.canlet.2024.216876_bib185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1570159X14666160223121002","article-title":"Nanotechnology applications for diffuse intrinsic pontine glioma","volume":"15","author":"Bredlau","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.canlet.2024.216876_bib186","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11185","article-title":"Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma","volume":"7","author":"Nikbakht","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216876_bib187","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201800479","article-title":"Signal transduction in diffuse intrinsic pontine glioma","volume":"19","author":"Duchatel","year":"2019","journal-title":"Proteomics"},{"key":"10.1016\/j.canlet.2024.216876_bib188","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41388-021-02102-y","article-title":"Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies","volume":"41","author":"Findlay","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216876_bib189","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2023.03.007","article-title":"Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities","volume":"41","author":"Sun","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216876_bib190","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216876_bib191","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170329","article-title":"PI3K\/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma","author":"Duchatel","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216876_bib192","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1038\/s41467-022-32205-3","article-title":"Connecting omics signatures and revealing biological mechanisms with iLINCS","volume":"13","author":"Pilarczyk","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216876_bib193","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/neuonc\/noab016","article-title":"OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes","volume":"23","author":"Liao","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib194","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/neuonc\/noz057","article-title":"DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas","volume":"21","author":"Schramm","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216876_bib195","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","article-title":"Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma","volume":"6","author":"Lin","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"10.1016\/j.canlet.2024.216876_bib196","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41590-022-01215-0","article-title":"Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression","volume":"23","author":"Yeo","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2024.216876_bib197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2023.11.002","article-title":"A road map for the treatment of pediatric diffuse midline glioma","volume":"42","author":"Koschmann","year":"2024","journal-title":"Cancer Cell"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T15:17:31Z","timestamp":1714490251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524002696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":197,"alternative-id":["S0304383524002696"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216876","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216876"}}